BMO Capital Downgrades Graphite Bio Inc (GRPH) to Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. SPY
6. META
7. BA
8. HOOD
9. INTC
10. JBLU

Go back to BMO Capital Downgrades Graphite Bio Inc (GRPH) to Market Perform

Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease

January 5, 2023 4:05 PM EST

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the companys conclusion that the event is likely related to study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023.

The decision by Graphite Bio to voluntarily pause the CEDAR study follows a serious and unexpected adverse event of... More